Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 18-70 years.~* A diagnosis of SLE according to the ACR criteria (at least 4/11 criteria).~* Sufficient signs to diagnose active SLE nephritis.~* Serum creatinine concentration of \<= 5.0 mg/dL.~* Leucocyte counts \>= 4000/uL.~* Receiving OCS (\<= 1.0 mg/kg/day; a maximum dose of 80 mg/day).~* Prior treatment with cyclophosphamide, azathioprine, cyclosporin A, or any other immunosuppressive drugs.~Exclusion Criteria:~* Chronic infection of HIV, Hepatitis B, Hepatitis C.~* Acute infection including fungal, viral, bacterial or protozoal diseases.~* Liver toxicity (WHO CTC class 2 and higher). No adequate liver function (total bilirubin \> 25 umol/L = 1.4 mg/dL unless explained otherwise (e.g. inherited, hemolysis), SGOT \> 2.5 x N, SGPT \> 2.5 x N).~* Pregnant or lactating women~* Female patients of child bearing age without safe method of contraception.~* Anemia (hemoglobin \< 8.0 g/dL), leucopenia (leucocytes \< 4000/uL unless attributable to SLE: leucocytes \< 2000/uL), thrombocytopenia (platelets \< 50000/uL).~* Neutrophils below 1000/uL.~* Hypogammaglobulinemia below 400 mg/dL of serum IgG.~* Any other condition that in the eyes of the investigator might have rendered the patient unsuitable for participation in the study. This especially includes major and active SLE organ involvement other than the kidney. Patients with SLE involvement of the central nervous system are not allowed to be included into the study.~* History of malignancy.~* Current participation in another trial or lass than 6 months since participation in a similar trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): NKT-01

Based on this trial design, predict the completion outcome and termination type (if applicable).